Upstream of any GLP-1 protocol decision, the PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights including variants in FTO, GLP1R, and MC4R that shape baseline GLP-1, appetite-regulation, and energy-balance biology
Some benefits of FDA-approved GLP-1/GIP medications beyond weight loss are supported by emerging research and may vary based on individual health conditions, including: Improve blood sugar regulation, increase insulin sensitivity, and lower A1C Reduce long-term diabetic risks and protect pancreatic function Lower cholesterol, triglycerides, and blood pressure, supporting long-term cardiovascular health Show promising reductions in heart attacks and strokes in early studies Reduce liver fat and potentially improve metabolic fatty liver disease
These symptoms are typically brief and resolve without treatment
The DAPI staining determined the total cell count
Further detail of the algorithm can be found in ESM Methods
and trafficking survivors